https://www.sciencedaily.com/releases/2023/10/231018115605.htm
Glioblastoma (GBM), an aggressive brain cancer, is notoriously resistant to treatment, with recurrent GBM associated with survival of less than 10 months. Immunotherapies, which mobilize the body's immune defenses against a cancer, have not been effective for…
Create an account or login to join the discussion